Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, PK, PD, and food-effect study of ASN120290 in healthy adults and elderly subjects
NL-OMON47854Phase 1Active, not recruiting
- Sponsor
- QPS
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing ASN120290 with Placebo (2 arms). Primary endpoints: Single-dose safety and tolerability, Single-dose safety and tolerability in elderly subjects under fasted and fed conditions and 2 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
ASN120290
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NL-OMON47854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47854.